Go Pro
→ Elon Musk’s Hushed FCC Filing. Sept 25th. (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVRx, Inc. stock logo
CVRX
CVRx
$3.04
+1.3%		$3.78
$2.20
▼
$11.30
$80.99M0.76657,373 shs810,472 shs
Femasys Inc. stock logo
FEMY
Femasys
$2.59
+1.6%		$2.92
$2.02
▼
$22.20
$21.69M-2.07152,341 shs35,027 shs
Hyperfine, Inc. stock logo
HYPR
Hyperfine
$0.78
+1.5%		$0.90
$0.76
▼
$2.22
$83.22M1.41390,587 shs548,316 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.07
+4.5%		$1.93
$1.13
▼
$2.89
$88.90M0.34333,252 shs429,950 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVRx, Inc. stock logo
CVRX
CVRx
0.00%+5.56%+7.04%-38.59%-55.16%
Femasys Inc. stock logo
FEMY
Femasys
0.00%-6.83%-5.13%-35.89%-63.69%
Hyperfine, Inc. stock logo
HYPR
Hyperfine
0.00%-0.68%-13.21%-50.96%-44.35%
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.00%+11.89%-10.00%+62.35%+33.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVRx, Inc. stock logo
CVRX
CVRx
$3.04
+1.3%		$3.78
$2.20
▼
$11.30
$80.99M0.76657,373 shs810,472 shs
Femasys Inc. stock logo
FEMY
Femasys
$2.59
+1.6%		$2.92
$2.02
▼
$22.20
$21.69M-2.07152,341 shs35,027 shs
Hyperfine, Inc. stock logo
HYPR
Hyperfine
$0.78
+1.5%		$0.90
$0.76
▼
$2.22
$83.22M1.41390,587 shs548,316 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.07
+4.5%		$1.93
$1.13
▼
$2.89
$88.90M0.34333,252 shs429,950 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVRx, Inc. stock logo
CVRX
CVRx
0.00%+5.56%+7.04%-38.59%-55.16%
Femasys Inc. stock logo
FEMY
Femasys
0.00%-6.83%-5.13%-35.89%-63.69%
Hyperfine, Inc. stock logo
HYPR
Hyperfine
0.00%-0.68%-13.21%-50.96%-44.35%
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.00%+11.89%-10.00%+62.35%+33.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CVRx, Inc. stock logo
CVRX
CVRx
2.17
Hold$5.3074.34% Upside
Femasys Inc. stock logo
FEMY
Femasys
2.50
Moderate Buy$50.001,830.50% Upside
Hyperfine, Inc. stock logo
HYPR
Hyperfine
2.40
Hold$2.03159.12% Upside
Pulmonx Corporation stock logo
LUNG
Pulmonx
2.50
Moderate Buy$7.67270.37% Upside

Current Analyst Ratings Breakdown

Latest FEMY, HYPR, LUNG, and CVRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
Hyperfine, Inc. stock logo
HYPR
Hyperfine
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$2.00
8/25/2026
Pulmonx Corporation stock logo
LUNG
Pulmonx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/20/2026
Hyperfine, Inc. stock logo
HYPR
Hyperfine
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$2.00
8/18/2026
Femasys Inc. stock logo
FEMY
Femasys
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$10.00
8/17/2026
Femasys Inc. stock logo
FEMY
Femasys
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/17/2026
CVRx, Inc. stock logo
CVRX
CVRx
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$13.00 ➝ $5.00
8/14/2026
Femasys Inc. stock logo
FEMY
Femasys
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$10.00
8/10/2026
Hyperfine, Inc. stock logo
HYPR
Hyperfine
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$2.00 ➝ $1.60
8/7/2026
CVRx, Inc. stock logo
CVRX
CVRx
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Neutral$4.00
8/7/2026
CVRx, Inc. stock logo
CVRX
CVRx
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$4.00
8/7/2026
CVRx, Inc. stock logo
CVRX
CVRx
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$14.00 ➝ $3.50
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CVRx, Inc. stock logo
CVRX
CVRx
$56.65M1.43N/AN/A$1.50 per share2.03
Femasys Inc. stock logo
FEMY
Femasys
$2.29M9.48N/AN/A$2.01 per share1.29
Hyperfine, Inc. stock logo
HYPR
Hyperfine
$11.40M7.30N/AN/A$0.42 per share1.87
Pulmonx Corporation stock logo
LUNG
Pulmonx
$90.50M0.98N/AN/A$1.31 per share1.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CVRx, Inc. stock logo
CVRX
CVRx
-$53.31M-$1.98N/AN/AN/A-84.93%-152.35%-50.93%11/4/2026 (Estimated)
Femasys Inc. stock logo
FEMY
Femasys
-$18.63M-$3.53N/AN/AN/A-534.36%-225.97%-74.68%11/17/2026 (Estimated)
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-$35.57M-$0.38N/AN/AN/A-210.75%-97.88%-61.81%11/12/2026 (Estimated)
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$54M-$1.16N/AN/AN/A-55.03%-96.66%-38.32%11/11/2026 (Estimated)

Latest FEMY, HYPR, LUNG, and CVRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Femasys Inc. stock logo
FEMY
Femasys
-$1.31-$1.33-$0.02-$1.33$0.73 million$0.33 million
8/6/2026Q2 2026
CVRx, Inc. stock logo
CVRX
CVRx
-$0.5246-$0.53-$0.0054-$0.53$15.55 million$15.71 million
8/6/2026Q2 2026
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-$0.09-$0.09N/A-$0.09$4.14 million$3.90 million
7/29/2026Q2 2026
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.28-$0.24+$0.04-$0.24$22.39 million$22.76 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CVRx, Inc. stock logo
CVRX
CVRx
N/AN/AN/AN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
N/AN/AN/AN/AN/A
Hyperfine, Inc. stock logo
HYPR
Hyperfine
N/AN/AN/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CVRx, Inc. stock logo
CVRX
CVRx
2.94
8.04
6.87
Femasys Inc. stock logo
FEMY
Femasys
0.89
2.14
0.55
Hyperfine, Inc. stock logo
HYPR
Hyperfine
0.36
6.15
5.45
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.95
4.32
3.52

Institutional Ownership

CompanyInstitutional Ownership
CVRx, Inc. stock logo
CVRX
CVRx
75.27%
Femasys Inc. stock logo
FEMY
Femasys
65.27%
Hyperfine, Inc. stock logo
HYPR
Hyperfine
15.03%
Pulmonx Corporation stock logo
LUNG
Pulmonx
91.04%

Insider Ownership

CompanyInsider Ownership
CVRx, Inc. stock logo
CVRX
CVRx
16.60%
Femasys Inc. stock logo
FEMY
Femasys
7.75%
Hyperfine, Inc. stock logo
HYPR
Hyperfine
26.33%
Pulmonx Corporation stock logo
LUNG
Pulmonx
7.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
CVRx, Inc. stock logo
CVRX
CVRx
22326.64 million22.22 millionOptionable
Femasys Inc. stock logo
FEMY
Femasys
548.38 million7.73 millionNot Optionable
Hyperfine, Inc. stock logo
HYPR
Hyperfine
102106.05 million78.13 millionOptionable
Pulmonx Corporation stock logo
LUNG
Pulmonx
29642.95 million39.73 millionOptionable

Recent News About These Companies

Critical Comparison: Flora Growth (NASDAQ:FLGC) and Pulmonx (NASDAQ:LUNG)
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31034751
BlackRock Inc. Takes Position in Pulmonx Corporation $LUNG
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-takes-position-in-pulmonx-corporation-lung-2026-09-07/
Pulmonx (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 7,879 Shares of Stock
September 4, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lung-insider-buying-and-selling-2026-09-04/
Pulmonx (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 7,879 Shares of Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-pulmonx-nasdaq-lung-insider-geoffrey-beran-rose-sells-7879-shares-of-stock-2026-09-03/
Pulmonx (NASDAQ:LUNG) Insider Srikanth Radhakrishnan Sells 14,245 Shares of Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-pulmonx-nasdaq-lung-insider-srikanth-radhakrishnan-sells-14245-shares-of-stock-2026-09-03/
Pulmonx (NASDAQ:LUNG) General Counsel David Aaron Lehman Sells 14,334 Shares of Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-pulmonx-nasdaq-lung-general-counsel-david-aaron-lehman-sells-14334-shares-of-stock-2026-09-03/
Pulmonx (NASDAQ:LUNG) CEO Glendon French III Sells 41,882 Shares of Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-pulmonx-nasdaq-lung-ceo-glendon-french-iii-sells-41882-shares-of-stock-2026-09-03/
Pulmonx shares fall following recent gains
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/pulmonx-shares-fall-following-recent-gains/ar-AA2bv4Cc
Pulmonx Stock Drops Sharply Amid Profit-Taking and Tepid Earnings Outlook
September 3, 2026  |  stockinvest.usS
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354576/0/en/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Stonepine Capital Management LLC Purchases New Holdings in Pulmonx Corporation $LUNG
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-stonepine-capital-management-llc-purchases-new-holdings-in-pulmonx-corporation-lung-2026-08-28/
Almitas Capital LLC Buys New Position in Pulmonx Corporation $LUNG
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-almitas-capital-llc-buys-new-position-in-pulmonx-corporation-lung-2026-08-28/
Pulmonx to Participate in Upcoming Investor Conferences
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352387/0/en/pulmonx-to-participate-in-upcoming-investor-conferences.html
Primecap Management Co. CA Invests $6 Million in Pulmonx Corporation $LUNG
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-primecap-management-co-ca-invests-6-million-in-pulmonx-corporation-lung-2026-08-27/
ADAR1 Capital Management LLC Makes New Investment in Pulmonx Corporation $LUNG
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-adar1-capital-management-llc-makes-new-investment-in-pulmonx-corporation-lung-2026-08-27/
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
August 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2980306/pulmonx-corporation-lung-now-trades-above-golden-cross-time-to-buy?cid=cs-stocknewsapi-ft-fundamental_analysis|golden_crossover-2980306
Parkman Healthcare Partners LLC Takes $841,000 Position in Pulmonx Corporation $LUNG
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-parkman-healthcare-partners-llc-takes-841000-position-in-pulmonx-corporation-lung-2026-08-25/
Pulmonx Corp.
August 15, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/LUNG
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975196/what-makes-pulmonx-corporation-lung-a-strong-momentum-stock-buy-now?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_10-2975196
Pulmonx (LUNG) Q2 2026 Earnings Call Transcript
August 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pulmonx-lung-q2-2026-earnings-010204064.html
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
August 3, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2966809/pulmonx-lung-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_12_zacks_rank_upgrade-2966809

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Credo Technology logo displayed over a data center server room with a network cable and transceiver module.
Credo Technology Just Plunged 20%—Did the Market Overreact?
By Thomas Hughes | September 4, 2026
Intuit logo displayed over a desk with a laptop, coffee mug, notebook, plant, and financial chart printout.
Intuit’s Earnings Reset May Be More Pivot Than Plunge
By Jeffrey Neal Johnson | August 28, 2026
Guidewire logo displayed on a lit wall in a modern office lobby setting.
Why Guidewire’s Post-Earnings Plunge May Not Last
By Thomas Hughes | September 7, 2026
Advance Auto Parts logo displayed on a sign in a garage setting with tires, wheels, and automotive tools.
Advance Auto Parts Plunged, But Its Turnaround Is Still Working
By Thomas Hughes | August 21, 2026
A white J.B. Hunt semi-truck and trailer with the company logo driving on a highway at sunset.
J.B. Hunt's Stock Plunges After Market Misprices Profit Warning
By Thomas Hughes | September 18, 2026
CVRx stock logo

CVRx NASDAQ:CVRX

$3.04 +0.04 (+1.33%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$2.98 -0.06 (-2.14%)
As of 09/18/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Femasys stock logo

Femasys NASDAQ:FEMY

$2.59 +0.04 (+1.57%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$2.62 +0.03 (+1.27%)
As of 09/18/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Hyperfine stock logo

Hyperfine NASDAQ:HYPR

$0.78 +0.01 (+1.54%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$0.79 +0.00 (+0.29%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$2.07 +0.09 (+4.55%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$2.12 +0.05 (+2.17%)
As of 09/18/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas